Clinical Trial Update: XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval Randomized Control Trial (RCT) [Phase 4]

View source ↗

Summary

Phase 4 post-approval randomized trial in China evaluating the XIENCE V Everolimus-eluting coronary stent system was completed, with results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease
• Coronary Occlusion
• Coronary Restenosis
• Myocardial Ischemia
• Stent Thrombosis

Drugs mentioned

• XIENCE V Everolimus-Eluting Coronary Stent System (EECSS) (everolimus-eluting coronary stent)

Snippet

Sponsor: Abbott Medical Devices | Conditions: Coronary Occlusion, Thrombosis (Stent Thrombosis) | Phase 4 | Status: COMPLETED | Results posted: 2016-08-24